Institution identification

Institution ID

44251

Institution full name and acronym

IQVIA

Institution countries

United Kingdom

Type of institution

Non-Pharmaceutical company

Institution role

Data holder
Researcher

Institution website

ENCePP partner

Yes
Institution description
We share the vision to drive healthcare forward. To see how we can help accelerate progress and achievements. It’s bigger than better clinical trials. Or advances in technologies and analytics. Or faster insights. It’s about exploring a new path to better health outcomes via Human Data Science. Our global scientific, RWE and operational experts are developing innovative methods for RWE study design and execution combining secondary and primary data directly from patients and physicians. Applications include:
- Post-authorization safety studies (PASS).
- Post-authorization effectiveness studies (PAES).
- Drug Utilization studies (DUS).
- Risk Evaluation and Mitigation Strategy (REMS).
- EU Risk Management Plan.
- Pregnancy Registries.
- Vaccine.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

115055-A prospective study to estimate the incidence of diseases specified as adverse events of special interest, of other adverse events leading to hospitalisation or death, and of meningitis in infants and young children in sub-Saharan Africa prior to implementation of the RTS,S/AS01E candidate vaccine (EPI-MALARIA 002 VS AME)
A Drug Utilisation Study extension (DUS ext.) of valproate and related substances, in Europe, using databases (VALNAC09343)
A drug utilisation study to assess the effectiveness of risk minimisation measures and describe the prescribing practices of Doreta SR and tramadol/paracetamol combinations in Europe (DUS Doreta SR and tramadol/paracetamol combination)
A drug utilization study (DUS) of alirocumab in Europe to assess the effectiveness of the dosing recommendation to avoid very low LDL-C levels
A Drug Utilization Study of SEASONIQUE in Europe
A Drug Utilization Study to Evaluate the Effectiveness of Risk Minimization Measures (RMMs) for Abrocitinib in the EU Using Electronic Healthcare Data (B7451085)
A Global Cross-sectional Survey to Capture Awareness and Knowledge of Mesenchymal Stem Cell (MSC) Therapy by Gastroenterologists and Colorectal Surgeons
A Joint Drug Utilisation Study (DUS) of valproate and related substances, in Europe, using databases
A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess the Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab (SIMA PASS)
A Non-Interventional Multi-Database Post-Authorisation Study to Assess PregnancyRelated Safety Data from Women with SLE Exposed to Anifrolumab (ROSE PASS)
A Non-Interventional Post-Authorization Safety Study (PASS) for Active Safety Surveillance of Recipients of the Pfizer-BioNTech COVID-19 mRNA vaccine in the EU
A non-interventional register-based comparative effectiveness study of rhFSH-alfa reference product vs. highly purified human menopausal gonadotropin or rhFSH-alfa biosimilar products for ovarian stimulation in in vitro fertilization or intracytoplasmic sperm injection treatment in Denmark and Sweden – The Nordic Follitropin Alfa Comparative Effectiveness Study (NORD-FACE)
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists based Glucose Lowering Drugs (EXCEED)
A post-authorisation safety study (PASS) to evaluate cardiovascular events in adult patients with obstructive sleep apnoea (OSA) treated with solriamfetol (JZP865-401)
A post-authorisation safety study (PASS) to evaluate the long-term cardiovascular and psychiatric safety profile of methylphenidate (MPH) in adult patients with attention deficit/hyperactivity disorder (ADHD) in European Countries (PASS on methylphenidate in adults)
A post-authorization safety study (PASS) to evaluate the paternal exposure to valproate and the risk of neurodevelopmental disorders including autism spectrum disorders as well as congenital abnormalities in offspring - a population-based retrospective study
A Post-Marketing Near Real-Time Safety Surveillance of Respiratory Syncytial Virus Vaccine for Guillain-Barre Syndrome (GBS) among Older Adults in the United States
A Prospective, Observational Cohort Study to Assess Long-Term Safety in Patients Prescribed Epidyolex® with a Focus on Drug-induced Liver Injury (DILI)
A registry-based non-interventional post-authorization safety study to evaluate the long-term safety of dupilumab in children aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis using the PEDISTAD registry: a cohort design
A retrospective cohort study to investigate the initiation and persistence of dual antiplatelet treatment after acute coronary syndrome in a Finnish setting – THALIA
A Retrospective Observational Study to describe the Effectiveness and Safety of Vedolizumab With or Without Budesonide Induction Therapy Among Patients with Moderate to Severe Crohn’s Disease (Vedo-BuDy)
Alecensa Survey to Prescribers: Effectiveness Measure to Investigate the Correct Implementation of Alecensa Label Guidance by Prescribers
An Active Surveillance Study to Monitor the Real-World Long-term Safety of Somatrogon Among Paediatric Patients in Europe
An International, Multicenter, Non-interventional Post-Authorization Safety Study to Evaluate the Effectiveness and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) treated in Real-World Settings (MagnetisMM-16)
An Observational Cohort Study on Multiple Myeloma Patients in Finland
An Observational Multi-Country Post-Authorisation Safety Study to Evaluate the Risk of Serious Adverse Cardiovascular Events in Adolescent and Adult Patients with Severe Asthma taking Tezepelumab (TRESPASS)
An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Drug Utilization in Selected European Populations
An Observational Study of Xeljanz® (tofacitinib citrate) and Biologic Rheumatoid Arthritis Treatments to Characterize their General Treatment Patterns, Effectiveness and Safety in a Real-World Taiwanese Population
ARIA: Real-world utilization and outcomes with dacomitinib first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi center chart review (A7471067)
ASSOCIATION BETWEEN THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME (TTS) OR THROMBOEMBOLIC EVENTS, AND COVID-19 VACCINES
Characteristics of IPF patients initiating nintedanib, pirfenidone or no antifibrotic treatment in the US
Characterization of neurodevelopmental disorders in children exposed in utero to valproate and/or other antiepileptic drugs with long-term follow-up: retrospective study of multiple European data sources (AVALON)
Comparative risk of the incident cancer between histamine-2 receptor antagonists (Risk of cancer between H2RAs)
Comparison of outcomes in patients undergoing major planned surgeries before vs. after the implementation of Patient Blood Management (PBM): a retrospective study in four European countries
Consequences for life of children with in utero exposure to metformin in Finland (CLUE) – a register-based cohort study
CROSSROADS-1: Treatment Outcomes among Tezspire Users: A Claims Data Study (20230159)
Direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C virus (HCV) infection and the risk of hepatocellular carcinoma (HCC) recurrence: A protocol for a systematic literature review
Drug utilization study of dexamfetamine in European countries (DUS of dexamfetamine)
Dulaglutide and Potential Risks of Pancreatic Cancer and Thyroid Cancer: A Non-Interventional PASS (H9X-MC-B013)
Effectiveness and Safety of Enoxaparin: Higher versus Standard Dose for Thromboprophylaxis in Patients of Varying Body Mass Index – A Retrospective Observational Cohort Study Using Real World EHR and Claims Data
EHDS2 Pilot Use Case: Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV-2 during the Omicron period.
EPID Multiple Sclerosis Pregnancy study - Pregnancy outcomes in Multiple Sclerosis populations exposed and unexposed to interferon beta - a register-based study in the Nordic countries
Evaluation of the effectiveness of additional risk minimisation measures (aRMMs) that aim to reduce the risks of phototoxicity, squamous cell carcinoma (SCC) of the skin and hepatic toxicity in patients receiving voriconazole in Saudi Arabia
Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey among Health Care Professionals to Assess their Knowledge on Dosing and Administration of Obizur® (Susoctocog alfa) in 6 European Countries
GENESIS: AIMOVIG® Pregnancy Exposure Registry (20180125)
Health Care Professional survey on understanding of key risk minimisation measures related to interstitial lung disease (ILD) / pneumonitis with Trastuzumab Deruxtecan treatment
Hydroxychloroquine safety and potential efficacy as an antiviral prophylaxis in light of potential wide-spread use in COVID-19: a multinational, large-scale network
cohort and self-controlled case series study
Impact of EU label changes for medicinal products containing methotrexate for weekly administration: risk awareness and adherence, A survey study
Incidence of Aicardi-Goutières syndrome (AGS) and KCNT1-related epilepsy in Denmark
INFORM - Interferon-Beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-Based Drug Utilisation Study in Finland and Sweden
Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine − CLARION
LONG-TERM NON-INTERVENTIONAL SAFETY STUDY OF EMICIZUMAB TREATMENT IN PATIENTS WITH MODERATE HAEMOPHILIA A AND SEVERE BLEEDING PHENOTYPE (STUDY BO44691, PASS)
Mavacamten Real-World Safety: a post-authorisation multi-national, long-term, observational study in patients with obstructive Hypertrophic Cardiomyopathy (oHCM) in the real-world setting in Europe (CV027-013)
Moderna mRNA-1273 Observational Pregnancy Outcome Study (COVID-19)
MulTinational database cohoRt study to assess adverse cardIovascular and cereBrovascular outcomes in patiEnts (TRIBE) with chronic obstructive pulmonary disease
Natural history of coagulopathy and use of anti-thrombotic agents in COVID-19 patients and persons vaccinated against SARS-CoV-2
Observational study assessing incidence of osteosarcoma among Forteo(teriparatide) users by linking state cancer registry data to large national pharmacy database data (B3D-MC-GHBX Addendum 2.3)
Pancreatic Cancer and Thyroid Cancer Risks with Dulaglutide Treatment
Patisiran-LNP Pregnancy Surveillance Program
Persistence and adherence to novel systemic pharmacological treatment of moderate to severe psoriasis vulgaris and psoriatic arthritis – A register-based cohort study in Finland and Sweden
Post Authorisation Safety Study (PASS): an European observational cohort of patients with type 1 diabetes treated via intraperitoneal route with Insuman Implantable 400 IU/mL in Medtronic MiniMed implantable pump (IIMOS)
Post-authorisation safety study to assess the risk of urinary tract malignancies in relation to empagliflozin exposure in patients with type 2 diabetes: a multi-database European study (PASS DiabCancer)
Post-authorisation Safety Study to Evaluate the Long-term Safety of Dexamfetamine (Amfexa) (PASS for dexamfetamine)
Post-Marketing Safety of SARS-CoV-2 mRNA-1273 Vaccine in the US: Active Surveillance, Signal Refinement and Self-Controlled Risk Interval (SCRI) Signal Evaluation in HealthVerity (COVID-19)
Prescriber survey to evaluate the awareness to risk minimisation measures for mitoxantrone-containing medicinal products in the treatment of patients with highly active relapsing multiple sclerosis associated with rapidly evolving disability
preventive TReatment of mIgraine: oUtcoMes for Patients in real-world Healthcare systems [TRIUMPH] (15Q-MC-B004)
Prospective International Observational Cohort Study Assessing Safety Outcomes Among Squamous Non-small Cell Lung Cancer Patients Treated with Necitumumab in Combination with Gemcitabine and Cisplatin in Comparison to Patients Treated with Cisplatin-based Doublets (I4X-MC-B002)
Prospective observational study to assess the long term safety profile of venetoclax in a Swedish cohort of Chronic Lymphocytic Leukaemia (CLL) patients
Ranitidine and other histamine H2-receptor antagonists – a drug utilisation study
Real-world Evidence on Diagnosed Gastroparesis in Europe: Multi-database Observational Epidemiological Study (TAK-906-5003)
Registry to study factors that may impact COVID-19 occurrence and severity (CARE)
Retrospective observational study on the effect of vedolizumab treatment on patients with inflammatory bowel disease and extraintestinal manifestations. The EMOTIVE study
Risk Factors Associated with Severe Hypoglycemia Among Patients with Type 2 Diabetes Mellitus Treated with Insulin (Risk factors for severe hypoglycemia)
Risk of subsequent cardiovascular events in patients discharged after myocardial infarction - Perseus (PERSEUS)
Severe hypersensitivity reactions associated with i.v. iron containing medicinal products in countries of the European Economic Area – before and after implementation of risk minimisation measures
Single-arm studies with external comparators for cancer drug development: a statistical methodology study to evaluate External Comparator Arm (ECA) study results versus Randomised Controlled Trial (RCT) results
Surveys among Health Care Professionals and Patients to assess their knowledge and behaviour with respect to the new (2018) Risk Minimization Measures for valproate use in Europe. (VALNAC09348)
The risk of musculoskeletal adverse outcomes after treatment with endocrine blocking treatments for breast cancer (MSKAI)
Tralokinumab real world clinical use: An observational cohort study of atopic dermatitis patients prescribed tralokinumab (TRACE)
Utilisation disease-modifying anti-rheumatic drugs (DMARDs) used for the treatment of rheumatoid arthritis: protocol for a multi-database real-world cohort study